Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceuticallyacceptable salts, and prodrugs thereof； compositions of the new compounds,either alone or in combination with at least one additional therapeutic agent,with a pharmaceutically acceptable carrier； and uses of the new compounds, eitheralone or in combination with at least one additional therapeutic agent, in theprophylaxis or treatment of proliferative diseases characterized by the abnormalactivity of growth factors, protein serine/threonine kinases, and phospholipidkinases.
